Compare TBHC & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBHC | EVAX |
|---|---|---|
| Founded | 1966 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.4M | 42.7M |
| IPO Year | N/A | 2021 |
| Metric | TBHC | EVAX |
|---|---|---|
| Price | $1.20 | $6.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | ★ 117.9K | 100.4K |
| Earning Date | 12-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,610,000.00 | $7,650,000.00 |
| Revenue This Year | N/A | $128.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 132.17 |
| 52 Week Low | $1.05 | $1.20 |
| 52 Week High | $2.40 | $12.15 |
| Indicator | TBHC | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 50.34 |
| Support Level | $1.18 | $6.15 |
| Resistance Level | $1.30 | $6.70 |
| Average True Range (ATR) | 0.07 | 0.51 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 24.18 | 41.88 |
The Brand House Collective Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.